Welcome to our dedicated page for Pediatrix Medical Group SEC filings (Ticker: MD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pediatrix Medical Group, Inc. filings document the public-company disclosures of a Florida physician-services operator focused on obstetrics, maternal-fetal medicine, neonatology and pediatric subspecialty care. Recent Form 8-K reports furnish operating results, including net revenue, earnings measures, same-unit revenue drivers, reimbursement factors, patient volume trends and hospital-based practice activity.
Proxy and governance filings cover director elections, shareholder voting results, executive compensation, pay-versus-performance data and the Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan. Other material-event reports address board appointments, Regulation FD disclosures and common-stock repurchase authorizations.
Pediatrix Medical Group, Inc. is holding its 2026 Annual Shareholders’ Meeting as a virtual-only webcast on May 7, 2026, asking investors to elect nine directors, ratify PricewaterhouseCoopers LLP as auditor, approve 2025 executive pay on an advisory basis, and approve the Second Amended and Restated 2008 Incentive Compensation Plan.
Shareholders of record at the close of business on March 9, 2026, when 83,072,104 common shares were outstanding, are entitled to vote. The board recommends voting “FOR” all four main proposals and uses majority voting in uncontested director elections with a resignation policy for nominees receiving more “against” than “for” votes.
The proxy details Pediatrix’s governance structure, including combined Chair/CEO with a Lead Independent Director, fully independent key board committees, cybersecurity and sustainability oversight, and codes of conduct and insider trading policies. It also explains a largely performance-based pay program tied to Adjusted EBITDA, ROIC and strategic goals, with strong prior say‑on‑pay support and a formal sustainability program that included $2.6 million in 2025 charitable donations.
Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore reported equity transactions in company common stock. She acquired 39,925 shares on March 1, 2026 as a share award tied to performance conditions from a program established on March 1, 2023.
On the same date, 26,931 shares were withheld to satisfy tax obligations upon vesting of shares at a price of $19.85 per share. After these direct transactions, she held 149,236 shares directly. An additional 52,598 shares are held indirectly through a trust for which she and her spouse serve as trustees.
Pediatrix Medical Group, Inc. reported that its EVP, CFO and Treasurer, Kasandra H. Rossi, had 3,676 shares of common stock withheld on a Form 4 filing. These restricted shares were withheld at $19.85 per share to cover taxes due upon vesting, rather than being sold in the open market.
After this tax-withholding disposition, Rossi directly holds 73,300 shares of Pediatrix common stock. This type of transaction is a routine administrative step tied to equity compensation vesting.
Pediatrix Medical Group reported stronger profitability for the quarter and year ended December 31, 2025. For the fourth quarter, diluted EPS was $0.40, with Adjusted EPS of $0.50 on net revenue of $493.8 million, down slightly from $502.4 million a year earlier. Same-unit net revenue grew 4.0%, driven by a 6.7% increase from reimbursement-related factors, while same-unit patient service volumes declined 2.7%.
For full-year 2025, net income was $165.4 million versus a net loss of $99.1 million in 2024, translating to diluted EPS of $1.94 compared with a loss of $1.19. Adjusted EBITDA rose to $275.6 million from $224.0 million, and full-year Adjusted EPS increased to $2.04 from $1.51.
Liquidity and leverage also improved. Cash and cash equivalents increased to $375.2 million from $229.9 million, while total debt decreased to $597.3 million from $617.7 million. For 2026, the company projects Adjusted EBITDA between $280 million and $300 million.
Pediatrix Medical Group, Inc. disclosed that its chief executive officer, who also serves as a director, sold 23,000 shares of Pediatrix common stock on December 15, 2025. The shares were sold at a weighted average price of $22.41 per share, with individual sale prices ranging from $22.00 to $22.62.
After completing this transaction, the insider directly beneficially owned 302,805 shares of Pediatrix common stock. The sale was reported as a disposition of non-derivative securities held directly by the reporting person.
Pediatrix Medical Group, Inc. (MD) reported an insider stock sale by a director. On 11/17/2025, the reporting person sold 10,478 shares of common stock in an open-market transaction coded "S" at a weighted average price of $23.00 per share, with individual trade prices ranging from $23.00 to $23.02.
After this transaction, the director beneficially owns 59,101 shares of Pediatrix common stock in direct form. The filing notes that detailed trade-by-trade pricing within the reported range is available upon request.
MD filed a Form 144 notice covering a planned sale of common stock. The filing states an intent to sell 10,478 common shares, with an aggregate market value of $240,994, on the NYSE, with an approximate sale date of 11/17/2025. The filing reports that these shares were acquired through stock plan activity from the issuer on several dates in 2021 and 2022. It also notes that total shares of the same class outstanding are 85,877,386. The signer represents that they are not aware of any material adverse, nonpublic information about the issuer’s operations.
Pediatrix Medical Group (MD) reported an insider transaction by a Director. On 11/06/2025, the reporting person sold 10,000 shares of common stock (code S) at a weighted average price of $21.65, with individual trade prices ranging from $21.51 to $21.76.
Following the sale, the reporting person beneficially owned 32,232 shares, held directly. The footnote states the seller will provide full trade-by-trade details within the disclosed price range upon request.